AIDS Therapy

Board recommends to breaking code of Coviracil pivotal trial early

Published in AIDS Weekly, October 7th, 2002

Triangle Pharmaceuticals, Inc., (VIRS) announced positive findings from FTC-301, an ongoing pivotal phase III trial of Coviracil (emtricitabine), its nucleoside reverse transcriptase inhibitor for the treatment of HIV disease.

With these results, the company confirmed plans to submit an NDA in the third quarter of this year.

FTC-301 is an ongoing 48-week, double-blind, placebo-controlled phase III trial comparing once-a-day Coviracil to Zerit (stavudine) given twice daily, each combined within a background regimen of Sustiva (efavirenz) and Videx EC (didanosine). A total of 571 patients were enrolled in the United States, Europe, Mexico, and South...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2002-10-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry